With The positive result of the first phase III study, coupled with the positive responses of nurses and patients, AcelRx Pharmaceuticals (ACRX) saw a substantial increase in its share price, reaching a high of $5.19 in late November. As is often…
Tag: stock market
AcelRx Pharma Selloff Caused By Error In Recent Press Release
On March 12th, Acelrx (ACRX) released a pr covering its last quarter’s earnings. In the pr, the company stated that it had cash to last only to Q3 of this year. However, in the official conference call minutes, the company…
CORRECTED CHARTS: Chart and commentary on $ATHX and others + Trading Technicals
Please excuse the green bed sheet in the background. We were trying different techniques for effects and obviously it did not work! Charts and Commentary on $ATHX and others.. Honoring Dr. King by following his example of looking at a…
Charts and commentary on $ATHX and others + Trading analysis. Honor Dr. King today.
Please excuse the green bed sheet in the background. We were trying different techniques for effects and obviously it did not work! Charts and Commentary on $ATHX and others.. please note; the charts on the right side get cut off…
Athersys, Inc. (ATHX) Beginning Due Diligence (chart technicals to come in seperate post)
Beginning points of Due Diligence for Athersys (ATHX) I am long the stock from $1.24. My Short Term catalyst Price Target opinion is $1.55 to $1.75, and $2.75 based on if positive Phase II data is reported. Multiple 2013 Catalysts…
Midweek Biopharma Update – $BLRX $PATH $NEPT and others + Twitter bashers (Video)
Midweek Biopharma Update – $BLRX $PATH $NEPT and others + Twitter bashers commentary. YouTube Video, enjoy!
Voce Capital Management Goes Hardball With Proxy Fight Against Obagi Board
Another chapter has been written on the nearly year long effort by Voce Capital management to get Obagi Medical Products (OMPI) sold, when on Monday, 12/3/12, Voce made public another letter sent to the Obagi Board of Directors (BOD) In…
